Iksuda Therapeutics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.glythera.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)IKS014 in Advanced Solid Tumors That Express HER2
Phase 1
Recruiting
- Conditions
- Breast CancerGastric CancerGastroesophageal-junction Cancer
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Iksuda Therapeutics Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT05872295
- Locations
- 🇦🇺
Macquarie University, Sydney, New South Wales, Australia
🇦🇺Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit, Concord, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
IKS03 in Advanced B cell NHL
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Iksuda Therapeutics Limited
- Target Recruit Count
- 80
- Registration Number
- 2024-512415-45-00
- Locations
- 🇮🇹
Humanitas Mirasole S.p.A., Rozzano, Italy
🇮🇹Ospedale San Raffaele S.r.l., Milan, Italy
🇮🇹Istituto Europeo Di Oncologia S.r.l., Milan, Italy
News
No news found